From residue to cancer risk: How thirdhand smoke drives cancer hallmarks
World Journal of Clinical Oncology · 24.06.2026 · 17 (6)
DOI: 10.5306/wjco.121469 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Clinical Oncology, online erschienen am 24.06.2026. Verfasst von Jian-Hua Mao und 1 weiteren Autor:innen. Die Arbeit nennt 65 Literaturangaben.
Abstract (Originalsprache)
Thirdhand smoke (THS) is a reservoir of toxic compounds that persist in indoor environments and on surfaces long after active smoking has ceased. Major THS chemicals, including nicotine, tobacco-specific nitrosamines, polycyclic aromatic hydrocarbons, and heavy metals, can induce DNA damage, epigenetic alterations, oxidative stress, and chronic inflammation. These biological changes contribute to one or more canonical hallmarks of cancer. In this minireview, we propose an integrated mechanistic framework that incorporates the hallmarks of cancer into environmental exposure risk assessment. This framework offers a system-level approach to carcinogenicity assessment that transcends the limitations of conventional single-endpoint toxicological assays. As a case application, we systematically analyze how THS chemicals disrupt specific cancer hallmarks and delineate the molecular and cellular mechanisms through which persistent tobacco smoke residues promote carcinogenesis. These insights establish a mechanistically grounded framework for assessing the environmental cancer hazard associated with THS.
Zitieren
APA
Mao, J., & Chang, H. (2026). From residue to cancer risk: How thirdhand smoke drives cancer hallmarks. World Journal of Clinical Oncology, 17(6). https://doi.org/10.5306/wjco.121469
Vancouver
Mao J, Chang H. From residue to cancer risk: How thirdhand smoke drives cancer hallmarks. World Journal of Clinical Oncology. 2026;17(6). doi:10.5306/wjco.121469
BibTeX
@article{Mao2026,
author = {Mao, Jian-Hua and Chang, Hang},
title = {From residue to cancer risk: How thirdhand smoke drives cancer hallmarks},
journal = {World Journal of Clinical Oncology},
year = {2026},
volume = {17},
number = {6},
doi = {10.5306/wjco.121469}
}
EUVIMED